2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.24 (Poster) FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations

PP01.24 (Poster) FURVENT: Global, Phase 3 Trial Testing Furmonertinib versus Chemotherapy as First Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations

Back to course

Pdf Summary

The FURVENT trial is a global, phase 3 study that is evaluating the efficacy and safety of furmonertinib, an EGFR inhibitor, compared to chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Furmonertinib is an oral drug that targets EGFR mutations and has been granted FDA Breakthrough Therapy Designation.<br /><br />EGFR exon 20 insertion mutations occur in approximately 2% of NSCLC cases and account for about 9% of all EGFR mutations in NSCLC. The current standard of care for these patients is platinum-based chemotherapy. However, the ongoing phase 1b FAVOUR study has shown promising efficacy of furmonertinib in both treatment-naïve and previously treated NSCLC patients with these mutations.<br /><br />In treatment-naïve patients, furmonertinib demonstrated a confirmed objective response rate of 78.6% and a median duration of response of 15.2 months. The responses were consistent across different types of EGFR exon 20 insertion mutations.<br /><br />The FURVENT trial aims to enroll 375 patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The patients will be randomized to receive either furmonertinib 160 mg, furmonertinib 240 mg, or platinum-based chemotherapy. The primary endpoint of the trial is progression-free survival (PFS), with overall survival (OS), objective response rate (ORR), and duration of response (DOR) being secondary endpoints.<br /><br />The trial is ongoing with global enrollment in multiple countries. The statistical analysis will compare the PFS between the furmonertinib treatment arms and the chemotherapy arm. The trial design also includes a crossover phase, where patients from the chemotherapy arm with disease progression can switch to furmonertinib therapy.<br /><br />Overall, the FURVENT trial is investigating the potential of furmonertinib as a first-line treatment option for NSCLC patients with EGFR exon 20 insertion mutations and aims to provide valuable data on its efficacy and safety compared to chemotherapy.

Asset Subtitle

John Le

Keywords

FURVENT trial

furmonertinib

EGFR inhibitor

chemotherapy

NSCLC

EGFR exon 20 insertion mutations

platinum-based chemotherapy

objective response rate

progression-free survival

global enrollment